A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder.

Trial Profile

A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity; Weight gain
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 04 Jun 2015 Planned End Date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 04 Jun 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top